Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates

被引:29
作者
Charreau, B
Ménoret, S
Tesson, L
Azimzadeh, A
Audet, M
Wolf, P
Marquet, R
Verbakel, C
Ijzermans, J
Cowan, P
Pearse, M
d'Apice, A
Soulillou, JP
Anegon, I
机构
[1] INSERM, U437, F-44093 Nantes, France
[2] Inst Transplantat & Rech Transplantat, Nantes, France
[3] Fdn Transplantat, Strasbourg, France
[4] Erasmus Univ, Rotterdam, Netherlands
[5] St Vincent Hosp, Immunol Res Ctr, Fitzroy, Vic, Australia
关键词
D O I
10.1007/BF03402074
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Production of transgenic pigs for multiple transgenes is part of a potential strategy to prevent immunological events involved in xenograft rejection. Use of a genetically engineerable rodent as a donor in primates could allow testing in vivo of the effects of different transgenes on controling xenograft rejection. As a first step in the development of a donor containing multiple transgenes, transgenic rats for human decay-accelerating factor (DAP) were used as heart donors to test their resistence against complement (C)-mediated rejection by non-human primates. Materials and Methods: Transgenic rats were generated by using a construct containing the human DAF cDNA under the transcriptional control of the endothelial cell (EC)-specific human ICAM-2 promoter. DAF expression was evaluated by immunohistology and by FAGS analysis of purified ECs. Resistance of transgenic hearts against C-mediated damage was evaluated by ex vivo perfusion with human serum and by transplantation into cynomolgus monkeys. Results: Immunohistological analysis of DAF expression in several organs from two transgenic lines showed uniform expression on the endothelium of all blood vessels. ECs purified from transgenic hearts showed 50% DAF expression compared to human ECs and >70% reduction of C-dependent cell lysis compared to control rat ECs. Hemizygous transgenic hearts perfused with human serum showed normal function for >60 min vs. 11.2 +/- 1.7 min in controls. Hemi- or homozygous transgenic hearts transplanted into cynomolgus monkeys showed longer survival (15.2 +/- 7 min and >4.5 hr, respectively) than controls (5.5 +/- 1.4 min). In contrast to hyperacutely rejected control hearts, rejected homozygous DAF hearts showed signs of acute vascular rejection (AVR) characterized by edema, hemorrhage, and an intense PMN infiltration. Conclusions: We demonstrate that endothelial-specific DAF expression increased heart transplant survival in a rat-to-primate model of xenotransplantation. This will aid in the analysis of AVR and of new genes that may inhibit this form of rejection, thus helping to define strategies for the production of transgenic pigs.
引用
收藏
页码:617 / 630
页数:14
相关论文
共 36 条
[1]   Assessment of hyperacute rejection in a rat-to-primate cardiac xenograft model [J].
Azimzadeh, A ;
Wolf, P ;
Dalmasso, AP ;
Odeh, M ;
Beller, JP ;
Fabre, M ;
Charreau, B ;
Thibaudeau, K ;
Cinqualbre, J ;
Soulillou, JP ;
Anegon, I .
TRANSPLANTATION, 1996, 61 (09) :1305-1313
[2]   Comparative study of target antigens for primate xenoreactive natural antibodies in pig and rat endothelial cells [J].
Azimzadeh, A ;
Wolf, P ;
Thibaudeau, K ;
Cinqualbre, J ;
Soulillou, JP ;
Anegon, I .
TRANSPLANTATION, 1997, 64 (08) :1166-1174
[3]   ACTIVATION OF INTRAGRAFT ENDOTHELIAL AND MONONUCLEAR-CELLS DURING DISCORDANT XENOGRAFT REJECTION [J].
BLAKELY, ML ;
VANDERWERF, WJ ;
BERNDT, MC ;
DALMASSO, AP ;
BACH, FH ;
HANCOCK, WW .
TRANSPLANTATION, 1994, 58 (10) :1059-1066
[4]  
Borche Luis, 1994, Xenotransplantation, V1, P125, DOI 10.1111/j.1399-3089.1994.tb00058.x
[5]   RELATIVE ROLES OF DECAY-ACCELERATING FACTOR, MEMBRANE COFACTOR PROTEIN, AND CD59 IN THE PROTECTION OF HUMAN ENDOTHELIAL-CELLS AGAINST COMPLEMENT-MEDIATED LYSIS [J].
BROOIMANS, RA ;
VANWIERINGEN, PAM ;
VANES, LA ;
DAHA, MR .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (12) :3135-3140
[6]  
Brouard S, 1999, J IMMUNOL, V162, P3367
[7]   Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage [J].
Byrne, G ;
McCurry, KR ;
Martin, MJ ;
McClellan, SM ;
Platt, JL ;
Logan, JS .
TRANSPLANTATION, 1997, 63 (01) :149-155
[8]   PROTECTION OF XENOGENEIC CARDIAC ENDOTHELIUM FROM HUMAN-COMPLEMENT BY EXPRESSION OF CD59 OR DAF IN TRANSGENIC MICE [J].
BYRNE, GW ;
MCCURRY, KR ;
KAGAN, D ;
QUINN, C ;
MARTIN, MJ ;
PLATT, JL ;
LOGAN, JS .
TRANSPLANTATION, 1995, 60 (10) :1149-1156
[9]   Transgenesis in rats: Technical aspects and models [J].
Charreau, B ;
Tesson, L ;
Soulillou, JP ;
Pourcel, C ;
Anegon, I .
TRANSGENIC RESEARCH, 1996, 5 (04) :223-234
[10]   PROTECTION OF RAT ENDOTHELIAL-CELLS FROM PRIMATE COMPLEMENT-MEDIATED LYSIS BY EXPRESSION OF HUMAN CD59 AND/OR DECAY-ACCELERATING FACTOR [J].
CHARREAU, B ;
CASSARD, A ;
TESSON, L ;
LEMAUFF, B ;
NAVENOT, JM ;
BLANCHARD, D ;
LUBLIN, D ;
SOULILLOU, JP ;
ANEGON, I .
TRANSPLANTATION, 1994, 58 (11) :1222-1229